{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:35:11Z","timestamp":1792802111162,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/gme.0b013e31821606c5","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T14:23:10Z","timestamp":1309443790000},"page":"1060-1066","source":"Crossref","is-referenced-by-count":61,"title":["Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women"],"prefix":"10.1097","volume":"18","author":[{"given":"Woraluk","family":"Somboonporn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunida","family":"Panna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerayut","family":"Temtanakitpaisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinaree","family":"Kaewrudee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukree","family":"Soontrapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210211","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.addr.2009.04.022","article-title":"Mirena (levonorgestrel intrauterine system): a successful novel drug delivery option in contraception.","volume":"61","author":"Rose","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"R3-7-20210211","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0344-0338(82)80072-1","article-title":"The protective role of progesterone in the prevention of endometrial cancer.","volume":"174","author":"Greenblatt","year":"1982","journal-title":"Pathol Res Pract"},{"key":"R4-7-20210211","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jnci\/91.13.1131","article-title":"Risk of endometrial cancer following estrogen replacement with and without progestins.","volume":"91","author":"Weiderpass","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R5-7-20210211","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1532-5415.1979.tb01673.x","article-title":"Reduced incidence of endometrial cancer among postmenopausal women treated with progestogens.","volume":"27","author":"Gambrell","year":"1979","journal-title":"J Am Geriatr Soc"},{"key":"R6-7-20210211","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/jnci\/89.15.1110","article-title":"Estrogen-progestin replacement therapy and endometrial cancer.","volume":"89","author":"Pike","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"R7-7-20210211","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1067\/mob.2000.108081","article-title":"Continuous combined hormone replacement therapy and risk of endometrial cancer.","volume":"183","author":"Hill","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"R8-7-20210211","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1080\/cmt.5.4.332.340","article-title":"Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3,175 women.","volume":"5","author":"de Lignieres","year":"2002","journal-title":"Climacteric"},{"key":"R9-7-20210211","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease.","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"key":"R10-7-20210211","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R12-7-20210211","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","article-title":"Breast cancer and hormone-replacement therapy in the Million Women Study.","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"key":"R13-7-20210211","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.288.7.872","article-title":"Postmenopausal hormone replacement therapy: scientific review.","volume":"288","author":"Nelson","year":"2002","journal-title":"JAMA"},{"key":"R14-7-20210211","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/AOG.0b013e3181bea950","article-title":"Endometrial cancer in postmenopausal women using estradiol-progestin therapy.","volume":"114","author":"Jaakkola","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R15-7-20210211","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(05)66455-0","article-title":"Endometrial cancer and hormone-replacement therapy in the Million Women Study.","volume":"365","author":"Beral","year":"2005","journal-title":"Lancet"},{"key":"R17-7-20210211","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0378-5122(95)00906-2","article-title":"Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device.","volume":"22","author":"Raudaskoski","year":"1995","journal-title":"Maturitas"},{"key":"R18-7-20210211","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0378-5122(96)01087-0","article-title":"Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses.","volume":"26","author":"Antoniou","year":"1997","journal-title":"Maturitas"},{"key":"R19-7-20210211","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/07853890410032820","article-title":"Estrogen replacement therapy in combination with continuous intrauterine progestin administration reduces the amount of circulating oxidized LDL in postmenopausal women: dependence on the dose of progestin.","volume":"36","author":"Ahotupa","year":"2004","journal-title":"Ann Med"},{"key":"R20-7-20210211","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0015-0282(16)57365-8","article-title":"Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy.","volume":"63","author":"Suhonen","year":"1995","journal-title":"Fertil Steril"},{"key":"R21-7-20210211","first-page":"963","article-title":"Intrauterine release of levonorgestrel-a new way of adding progestogen in hormone replacement therapy.","volume":"79","author":"Andersson","year":"1992","journal-title":"Obstet Gynecol"},{"key":"R22-7-20210211","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0378-5122(03)00163-4","article-title":"Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT.","volume":"46","author":"Boon","year":"2003","journal-title":"Maturitas"},{"key":"R23-7-20210211","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1471-0528.2002.01167.x","article-title":"Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response.","volume":"109","author":"Raudaskoski","year":"2002","journal-title":"BJOG"},{"key":"R24-7-20210211","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0002-9378(95)90095-0","article-title":"Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.","volume":"172","author":"Raudaskoski","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"R26-7-20210211","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1136\/bmj.302.6791.1481","article-title":"Randomisation.","volume":"302","author":"Altman","year":"1991","journal-title":"BMJ"},{"key":"R28-7-20210211","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/aje\/kwj069","article-title":"Bias in clinical intervention research.","volume":"163","author":"Gludd","year":"2006","journal-title":"Am J Epidemiol"},{"key":"R29-7-20210211","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/ijc.25762","article-title":"Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study.","volume":"128","author":"Jaakkola","year":"2011","journal-title":"Int J Cancer"},{"key":"R30-7-20210211","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/09513590500099156","article-title":"Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women.","volume":"20","author":"Wildemeersch","year":"2005","journal-title":"Gynecol Endocrinol"},{"key":"R31-7-20210211","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1093\/humrep\/dei085","article-title":"Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women.","volume":"20","author":"Hampton","year":"2005","journal-title":"Hum Reprod"},{"key":"R32-7-20210211","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00042192-199906040-00003","article-title":"Effect of age on reasons for initiation and discontinuation of hormone replacement therapy.","volume":"6","author":"Ettinger","year":"1999","journal-title":"Menopause"},{"key":"R33-7-20210211","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0378-5122(02)00341-9","article-title":"Compliance with hormone replacement therapy in Thai women.","volume":"44","author":"Manonai","year":"2003","journal-title":"Maturitas"},{"key":"R34-7-20210211","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00042192-200007040-00010","article-title":"Important factors for use of hormone replacement therapy: a population-based study of Swedish women. The Women's Health in Lund Area (WHILA) Study.","volume":"7","author":"Li","year":"2000","journal-title":"Menopause"},{"key":"R35-7-20210211","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0029-7844(97)00264-0","article-title":"Hormone replacement therapy among Danish women aged 45-65 years: prevalence, determinants, and compliance.","volume":"90","author":"Oddens","year":"1997","journal-title":"Obstet Gynecol"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00042192-201110000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:36:05Z","timestamp":1786044965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00042192-201110000-00007"}},"subtitle":["systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e31821606c5","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}